←
Storm Therapeutics269 posts
Storm Therapeutics avatar

Storm Therapeutics

@storm_tx

STORM Therapeutics is a biotech company discovering and developing novel small molecule therapies for RNA modification enzymes for oncology and other diseases

◷ Joined June 2016▧ 129 Photos and videos
Storm Therapeutics avatar
Storm Therapeutics@storm_tx·Apr 16

📢 We’ve announced a $56 million Series C financing to support the advancement of STC‑15, our first‑in‑class, oral small‑molecule METTL3 inhibitor. The first patient has now been dosed in a Phase 2 monotherapy trial in selected sarcoma indications. bit.ly/3QeVxMH

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·Jan 8

Excited to team up with AlidaBio to explore how METTL3 inhibition affects RNA regulation in cancer patients. We're using AlidaBio's advanced sequencing platforms to analyze samples from our Phase 1/2 trials with STC-15, our first-in-class METTL3 inhibitor. bit.ly/49tpJd5

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·21 Oct 2025

Meet STORM at @ELRIG_SCIENCE Drug Discovery 2025! Join us for our poster presentations to explore the critical role of RNA-binding proteins in cellular replication stress mechanisms. 📍 Poster #163 📅 21 & 22 Oct 🕐 13:00-13:45 BST 📌 Beside the Tech Theatre

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·17 Oct 2025

📢 Discovery data to be unveiled at AACR-NCI-EORTC 2025 📢 STORM Therapeutics will present new data on #STM11315, its allosteric, potent & selective #DHX9 helicase inhibitor, on 24 October. 🗣️ Oral Presentation: 5:26–5:36 PM EDT 📌 Poster Presentation: 12:30–4:00 PM EDT

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·27 May 2025

Clinical milestone achieved & CMO appointed! The #firstpatient has been dosed in our collaboration with Coherus Biosciences, commencing a Phase 1b/2 study with STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab). bit.ly/3Z5nlVv

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·14 Nov 2024

Look out for the #STORM team at London Life Sciences Week! Our CEO, Jerry McMahon, will attend the upcoming @Jefferies London Healthcare Conference from 19-21 November alongside our CBO, Marguerite Hutchinson.

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·14 Nov 2024

Our Group Leader, Molecular Cell Biology, Alexandra Sapetschnig, is presenting at RNA Modifications and Epitranscriptomics on 15 November from 11:20-11:40 CET! Come along to hear about #STORM's first-in-class #METTL3 inhibitor #STC15 and new #clinical data presented at #SITC2024.

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·13 Nov 2024

Check out the latest insights from our CEO, Jerry McMahon, featured in an article by International Clinical Trials discussing the current field of Alzheimer’s disease, drugs, biomarkers, and the future of treatment options for #neurogenerativediseases: bit.ly/3YJimc7

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·11 Nov 2024

#STORM presents new #clinical data at #SITC2024 from its Phase 1 study evaluating #STC15. Highlights include promising signs of clinical activity observed in multiple tumor types and gene expression data showed upregulation of innate immunity pathways. Read more in the comments👇

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·4 Nov 2024

Visit our poster presentation at #SITC2024! 📝 Title: Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies 📅 Date: Saturday 9 November 📌 Abstract number: 676

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·23 Oct 2024

STORM is in Barcelona for the EORTC-NCI-AACR (#ENA) Symposium! Poster details below 👇 📢 Session Title: New therapies in immuno oncology 📅 Session Date and Time: 25 October, 09:00 - 15:00 CEST 🏢 Location: Exhibition Hall 📌 Catalog Number: 451 🗞️ Presentation Number: PB439

Storm Therapeutics avatar
Storm Therapeutics@storm_tx·18 Oct 2024

Thanks to @Cambridge_Uni for spotlighting us as one of '10 Cambridge spinouts changing the story of cancer'! Check out STORM in the article 👇 and discover how we are pioneering cellular reprogramming through RNA modifications to treat disease🧬#lifesciences #biotech #cancer

💡A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. Here's how 10 companies spun out of research at Cambridge are doing it: cam.ac.uk/stories/cambridge-… #ChangingTheStoryOfCancer